Lippi Giuseppe, Favaloro Emmanuel J
Section of Clinical Biochemistry, University of Verona, Piazzale LA Scuro, 10, Verona, 37134, Italy.
Haematology Department, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, NSW Health Pathology, Westmead, NSW, 2145, Australia.
Methods Mol Biol. 2017;1646:29-42. doi: 10.1007/978-1-4939-7196-1_2.
Hemostasis testing is critical to many hemorrhagic and thrombotic disorders, wherein laboratory diagnostics can provide critical information for diagnosis, prognostication, and therapeutic monitoring. Due to this crucial role in modern medicine, hemostasis tests should be carried out at their highest degree of quality, thus encompassing standardization and monitoring of all phases of the testing process. It is now clearly established that the preanalytical phase is the most critical and vulnerable part of the total testing process, since up to 70% of diagnostic errors are due to highly manual activities encompassing patient preparation and collection of biological samples, as well as handling, transportation, preparation and storage of blood specimens. Due to the peculiar sample matrix required for hemostasis testing (i.e., plasma anticoagulated with buffered sodium citrate), additional critical issues may impair the reliability of these tests. Therefore, this article aims to provide an updated overview of the most important preanalytical variables that may ultimately impair the quality of hemostasis and thrombosis testing.
止血检测对于许多出血性和血栓性疾病至关重要，实验室诊断可为诊断、预后评估和治疗监测提供关键信息。由于在现代医学中发挥着这一关键作用，止血检测应在最高质量水平上进行，从而涵盖检测过程所有阶段的标准化和监测。目前已明确，分析前阶段是整个检测过程中最关键且最易出问题的部分，因为高达70%的诊断错误源于包括患者准备、生物样本采集以及血液标本处理、运输、制备和储存等高度人工化的操作。由于止血检测所需的特殊样本基质（即使用枸橼酸钠缓冲液抗凝的血浆），其他关键问题可能会影响这些检测的可靠性。因此，本文旨在提供一份最新综述，介绍可能最终影响止血和血栓形成检测质量的最重要分析前变量。
